1999–2015年深圳市结核病细菌耐异烟肼、利福平流行趋势分析

新发传染病电子杂志 ›› 2017, Vol. 2 ›› Issue (1): 10-13.

1999–2015年深圳市结核病细菌耐异烟肼、利福平流行趋势分析

卢春容, 谭卫国, 卓志鹏, 吴清芳, 管红云, 季乐财, 余卫业

深圳市慢性病防治中心肺部疾病防治研究所,广东深圳 518020

收稿日期:2016-11-29 出版日期:2017-02-28 发布日期:2020-07-01
通讯作者: 余卫业,Email：ywy2002@126.com
基金资助:
“十二五”国家科技重大专项（2012ZX10004-903）; 广东省医学科学技术研究基金（A2015050）; 深圳市知识创新计划基础研究项目（JCYJ20160428145728055）

Analysis for epidemic trend of tuberculosis bacteria resistant to isoniazid and rifampin in Shenzhen from 1999 to 2015

LU Chun-rong, TAN Wei-guo, ZHUO Zhi-peng, WU Qing-fang, GUAN Hong-yun, JI Le-cai, YU Wei-ye

Institute of lung disease,Shenzhen Center for Chronic Disease Control,Guangdong Shenzhen 518020,China

Received:2016-11-29 Online:2017-02-28 Published:2020-07-01

摘要/Abstract

摘要： 目的分析深圳市结核病细菌耐异烟肼（isoniazid,H）、利福平（rifampiein,R）流行趋势及耐多药情况,为制定科学的防控策略提供依据。方法 1999–2015年深圳市各区结核病防治机构登记涂阳肺结核患者17,144例,经痰培养和菌种鉴定,对鉴定为结核分枝杆菌的16,846株菌株进行药敏结果分析,分析耐H、R流行趋势及耐多药情况。结果 16,846例肺结核患者中,户籍人口2458例（14.59%）,流动人口14,388例（85.41%）;总耐多药率为4.14%（697/16,846）,其中初治患者耐多药率为3.22%（509/15,793）,复治患者耐多药率为17.85%（188/1053）;17年来所有耐R病例中耐多药的发生率是70.69%（697/986）。近17年结核病患者结核分枝杆菌对H、R耐药频度以及总耐多药率、初治患者耐多药率总体呈下降趋势,差异有统计学意义（P值均<0.05）。复治患者耐多药率无下降趋势（P>0.05）。结论流动人口是深圳市结核病防控的重点人群。近17年来深圳市结核病结核分枝杆菌总耐多药率呈现总体平稳,缓慢下降趋势,但复治患者总耐多药率明显高于初治患者,且利福平耐药结核病患者发生耐多药的可能性很大。因此,仍需强化结核病控制策略,不断提高管治质量,有效遏制耐多药结核病疫情。

关键词: 结核病, 分枝杆菌, 耐药趋势, 深圳市

Abstract: Objective To provide evidence for developing scientific prevention and control strategies by analyzing the epidemic trends of tuberculosis bacteria resistant to Isoniazid(H),tuberculosis bacteria resistant to rifampicin(R),and multidrug-resistant situation in Shenzhen. Methods A total of 17 144 patients with smear-positive pulmonary tuberculosis were registered in Shenzhen during 1999-2015. Here were 16,846 strains identified as mycobacterium tuberculosis by cultured strain identification,which were used to analyze the epidemic trends of H,R,and multidrug-resistant situation. Results Among the 16,846 tuberculosis patients,2458(14.59%) cases had household registration and 14 388(85.41%) cases were floating population. The total multidrug-resistance rate was 4.14%(697/16,846),the initial multidrug-resistance rate and the acquired multidrug-resistance rate were 3.22%(509/15,793) and 17.85%(188/1053) respectively;70.69%(697/986) of H were multidrug-resistant tuberculosis in the 17 years. There were a downtrends in the frequentness of H and R,total multidrug-resistance rate and initial-resistance rate in the past 17 years(P<0.05). There was no down trend in the multidrug-resistance rate among the retreatment patients(P>0.05). Conclusion The floating population was the focus of tuberculosis prevention and control in Shenzhen. Totally,there was a down trend of multidrug-resistance rate in the past 17 years,but the multidrug-resistance rate among the retreatment patients was significantly higher than that among the untreated patients,and H were more likely to develop into multidrug-resistant tuberculosis. It is still needed to strengthen the TB control strategy,improve the quality of governance continuously,and curb the MDR-TB epidemic effectively.

Key words: Tuberculosis, Mycobacterium, Trends of drug resistance, Shenzhen city

卢春容, 谭卫国, 卓志鹏, 吴清芳, 管红云, 季乐财, 余卫业. 1999–2015年深圳市结核病细菌耐异烟肼、利福平流行趋势分析[J]. 新发传染病电子杂志, 2017, 2(1): 10-13.

LU Chun-rong, TAN Wei-guo, ZHUO Zhi-peng, WU Qing-fang, GUAN Hong-yun, JI Le-cai, YU Wei-ye. Analysis for epidemic trend of tuberculosis bacteria resistant to isoniazid and rifampin in Shenzhen from 1999 to 2015[J]. Electronic Journal of Emerging Infectious Diseases, 2017, 2(1): 10-13.

[1]	谭卫国, 管红云, 吴清芳, 陆普选, 洪创跃, 赖培烜, 李明珍, 陈蓉, 余卫业. 流动人口结核病防控创新策略与实施效果[J]. 新发传染病电子杂志, 2020, 5(3): 145-149.
[2]	卓志鹏, 吴清芳, 赖培烜, 卢春容, 余卫业, 谭卫国. 2018年深圳市医疗机构肺结核病例报告调查分析[J]. 新发传染病电子杂志, 2020, 5(3): 191-194.
[3]	许金卫, 张鑫, 陈震. 非结核分枝杆菌肺病与继发性肺结核的CT表现分析[J]. 新发传染病电子杂志, 2020, 5(2): 113-117.
[4]	邬宇美, 骆子义, 彭劲甫. 结核分枝杆菌16Sr RNA+DNA和23S DNA检测对肺结核的诊断及治疗状态评价[J]. 新发传染病电子杂志, 2020, 5(2): 118-121.
[5]	罗一婷, 翁榕星, 周芳, 余卫业, 陆普选. 2019 WHO全球结核报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2020, 5(1): 47-50.
[6]	袁婧, 李春华, 李奇穗, 余庆, 吕圣秀, 陈耀凯. 严重免疫缺陷时HIV/TB合并感染者胸部CT表现与CD4⁺T淋巴细胞计数水平的相关性研究[J]. 新发传染病电子杂志, 2019, 4(3): 145-148.
[7]	何俊其, 张立民, 郭艳红. 结核病患者药物性肝损伤预警模型的建立及验证研究[J]. 新发传染病电子杂志, 2019, 4(2): 117-120.
[8]	高祥, 叶涛生, 杨倩婷, 张明霞. 生物传感器技术在结核病检测中的研究进展[J]. 新发传染病电子杂志, 2019, 4(1): 48-51.
[9]	余卫业, 谭卫国, 罗一婷, 陆普选. 2018WHO全球结核报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2018, 3(4): 228-233.
[10]	杨松, 严晓峰. 结核病与糖尿病：相互关系和诊治的研究新进展[J]. 新发传染病电子杂志, 2018, 3(4): 234-238.
[11]	王毅翔, MyungJinChung, AliaksandrSkrahin, AlexRosenthal, AndreiGabrielian, MichaelTartakovsky, 于英杰, 陆普选. 与耐多药肺结核相关的放射学征象的文献分析[J]. 新发传染病电子杂志, 2018, 3(4): 244-253.
[12]	杨倩婷, 邓国防, 尤信信, 陈骑, 张明霞, 邓群益, 周一平. IP-10在结核患者中的表达及在诊断中的应用[J]. 新发传染病电子杂志, 2017, 2(4): 198-201.
[13]	陈心春, 温志华. 基于宿主基因定向治疗耐多药结核病：机遇与挑战[J]. 新发传染病电子杂志, 2017, 2(3): 129-132.
[14]	王玉臣, 陈福增, 黄滢睿, 张鹭, 刘军. 结核分枝杆菌PE31抗原的免疫原性及保护效果研究[J]. 新发传染病电子杂志, 2017, 2(3): 155-159.
[15]	宗兆婧, 荆玮, 霍凤敏, 尚媛媛, 梁倩, 李云絮, 逄宇, 黄海荣. 广泛耐药结核分枝杆菌对利奈唑胺的耐药情况分析[J]. 新发传染病电子杂志, 2017, 2(3): 160-163.